A new start­up thinks it's found a key to drug­ging 'dis­or­dered' pro­teins — and it has plen­ty of cash to get start­ed

The say­ing goes ne­ces­si­ty is the moth­er of in­ven­tion — and few ar­eas of drug de­vel­op­ment are in greater need than on­col­o­gy. A new start­up is now re­pur­pos­ing promis­ing tech­nol­o­gy to tack­le the hard­est-to-drug pro­teins, and a suite of big-name back­ers are buy­ing in.

Am­bagon Ther­a­peu­tics launched Fri­day with an $85 mil­lion A round and a world-class group of re­searcher-founders build­ing what are known as “mol­e­c­u­lar glues” to crack the code on a class of elu­sive cel­lu­lar pro­teins, the biotech said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER